Enterin Inc.
Improving the quality of life of patients with neurodegenerative conditions by repairing the gut-brain axis.
Philadelphia, United States
18 employees
Series Unknown
Total: $81.60M
Biopharma, Biotechnology
General Information
Get notified when Enterin Inc. moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Enterin Inc.
Get real-time alerts for funding, hiring, news, and 40+ signal types.
Start Tracking — FreeDiscover More
United States Market
Biopharma
About Enterin Inc.
Taxonomy: Neurodegenerative disease, Biopharmaceutical company, Parkinson's Disease, Clinical stage, Gut-brain axis, Enteric nervous system, Alpha-synuclein, Neurological disorders, Clinical trials, Synthetic derivatives, Endogenous hormones, Misfolded proteins, Quality of life, Medical community, Drug development
Funding Rounds & Investors (6)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Venture Round | •••••• | - | 06 Dec 2023 | |
| Convertible Note | •••••• | 1 |
|
03 Oct 2022 |
| Convertible Note | •••••• | - | 23 Mar 2021 | |
| Series C | •••••• | - | 14 Sep 2020 | |
| Series B | •••••• | 1 | •••• •••• | 01 Feb 2019 |
Enterin Inc. Alternatives & Competitors
Pioneering science beyond the brain to treat neurodegenerative diseases at their source
Cantabio aim to slow, stop and even prevent the onset & progression of neurodegenerative diseases.
Stopping the wave of neurodegeneration at its source
FAQ About Enterin Inc.
Don't just browse. Track.
Signal Tracker monitors Enterin Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.